Transplant-Associated Thrombotic Microangiopathy

Jeffrey Laurence, MD, provides an overview of transplant-associated thrombotic microangiopathy (TA-TMA), the associated risk factors, and the role of the complement pathway in TA-TMA development.

Parameswaran Hari, MD, reviews challenges in defining the incidence of transplant-associated thrombotic microangiopathy; an expert panel comments on the volume of autologous transplants performed in expert centers.

A panel of experts in hematopoietic stem cell transplantation examine their personal experience in the incidence of transplant-associated thrombotic microangiopathy in the adult and pediatric populations and the criteria used to diagnose.

The expert panel considers the time frame of transplant-associated thrombotic microangiopathy, the subtle signs to pay attention to, and testing for proteinuria.

Parameswaran Hari, MD, and Christine Duncan, MD, discuss the differences between uncontrolled vs self-limited transplant-associated thrombotic microangiopathy.

Jeffrey Laurence, MD, reviews the risk factors for developing transplant-associated thrombotic microangiopathy, and the panel discusses how risk affects their decision to change or modify treatment regimens.

The panel considers the development, morbidity, and survival of transplant-associated thrombotic microangiopathy associated with GVHD (graft-versus-host disease).

A panel of experts recall the challenges of accurate early detection of transplant-associated thrombotic microangiopathy and its importance for improved patient outcomes.

Jeffrey Laurence, MD, reviews the available interventions used to mitigate or treat transplant-associated thrombotic microangiopathy.

Experts in the field of hematopoietic stem cell transplantation provide their views and experiences with various interventions for managing transplant-associated thrombotic microangiopathy.

The panel reviews therapeutic options for managing transplant-associated thrombotic microangiopathy and the challenges associated with currently existing agents.

Jeffrey Laurence, MD, discusses the role of leptin in the MASP-2 pathway as well as coagulation and complement pathways.

Samer Khaled, MD reviews the design, results, and practical implications of the pivotal phase 2 trial of narsoplimab, a MASP-2 targeted monoclonal antibody under investigation for the treatment of thrombotic microangiopathy associated with hematopoietic stem cell transplantation.

The panel of transplant experts discuss the results of the phase 2 trial of narsoplimab and the pending FDA approval of this agent for treatment of transplant-associated of thrombotic microangiopathy.